Fibrotherapeutics Inc.

Fibrotherapeutics Inc. is a for-profit corporate entity registered in SAM.gov since August 2011, specializing in developing novel therapeutic peptides targeting fibrotic diseases across multiple organ systems. The company focuses on developing modified versions of the caveolin-1 scaffolding domain (CSD) peptide, which shows promise in treating various fibrotic conditions by suppressing profibrotic cellular mechanisms. Their research and development efforts are centered on creating water-soluble, proteolysis-resistant peptide compounds with improved pharmacological properties that can potentially treat complex medical conditions with limited current treatment options.

The company has secured multiple federal grant awards from civilian agencies, specifically from the National Institutes of Health, including the National Institute of Diabetes and Digestive and Kidney Diseases, National Heart Lung and Blood Institute, and National Institute of Arthritis and Musculoskeletal and Skin Diseases. These project grants, ranging from $675,480 to approximately similar amounts, focus on developing therapeutic compounds for specific fibrotic diseases, including chronic kidney disease, heart failure, scleroderma skin disease, and interstitial lung disease. Each grant involves preclinical research using mouse models to evaluate the efficacy, safety, and therapeutic index of modified CSD peptides. The research protocols consistently aim to suppress pathological effects in target organs by more than 50-75%, with a goal of developing lead compounds that can potentially provide more effective treatments with fewer side effects compared to existing FDA-approved drugs like pirfenidone and nintedanib.